Related Funds
| Fund Name | Location |
| Brighton Park Capital | Connecticut, Greenwich, United States |
| Broadband Capital Management | New York, New York, United States |
| Centiva Capital | Canada, Ontario, Toronto |
| CompanyFirst | Chicago, Illinois, United States |
| Dara Capital | Switzerland, Zürich, Zurich |
| Hefei Hi-Tech Venture Capital | Anhui, China, Hefei |
| Laurel Capital Partners | Pennsylvania, Radnor, United States |
| Nahkoda Capital | California, Palo Alto, United States |
| Shengda Huixin | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ensoma | $50M | 16 May 2023 | Boston, Massachusetts, United States | ||
Ensoma | $85M | 05 Jan 2023 | Boston, Massachusetts, United States | ||
Carisma Therapeutics | $30M | 21 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
SalioGen Therapeutics | $115M | 05 Jan 2022 | Burlington, Massachusetts, United States | ||
Platelet BioGenesis | $75M | 04 Nov 2021 | Newton, Massachusetts, United States | ||
EGenesis | $125M | 02 Mar 2021 | Cambridge, Massachusetts, United States | ||
Carisma Therapeutics | $12M | 01 Mar 2021 | Philadelphia, Pennsylvania, United States | ||
Ensoma | $70M | 11 Feb 2021 | Boston, Massachusetts, United States | ||
Carisma Therapeutics | $47M | 07 Jan 2021 | Philadelphia, Pennsylvania, United States |
– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ensoma | $50M | 16 May 2023 | Boston, Massachusetts, United States | ||
Ensoma | $85M | 05 Jan 2023 | Boston, Massachusetts, United States | ||
Carisma Therapeutics | $30M | 21 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
SalioGen Therapeutics | $115M | 05 Jan 2022 | Burlington, Massachusetts, United States | ||
Platelet BioGenesis | $75M | 04 Nov 2021 | Newton, Massachusetts, United States | ||
EGenesis | $125M | 02 Mar 2021 | Cambridge, Massachusetts, United States | ||
Carisma Therapeutics | $12M | 01 Mar 2021 | Philadelphia, Pennsylvania, United States | ||
Ensoma | $70M | 11 Feb 2021 | Boston, Massachusetts, United States | ||
Carisma Therapeutics | $47M | 07 Jan 2021 | Philadelphia, Pennsylvania, United States |
